Alvotech S.A. - רווח למניה לשנה מתגלגלת ALVO

Alvotech (ALVO) is a specialized biosimilar developer with robust scientific potential in oncology and immunology. The GURU.Markets system provides the current EPS YoY TTM growth rate, where -364.80 represents the latest level of this metric. Process optimization via external contractors and logistics accelerates the rollout of affordable, budget-friendly therapies to global markets, reducing the cost of treating complex pathologies.

Alvotech's ability to develop affordable biosimilars depends directly on overcoming patent barriers and securing regulatory approvals, which renders profits highly volatile. By analyzing the historical net income per share growth rate YoY ttm, an investor can observe the percentage change in EPS over the last 12 months, where peak values often signal that the asset is overvalued against a backdrop of high production costs.